[1]
European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017; Stockholm ECDC, 2018.
[2]
Placinta, C.M.; D’Mello, J.P.F.; MacDonald, A.M.C. A review of worldwide contamination of cereal grains and animal feed with Fusarium mycotoxins. Anim. Feed Sci. Technol., 1999, 78(1-2), 21-37.
[3]
Lemke, T.L.; Williams, D.A. Foye’s Principles of Medicinal Chemistry, 7th ed; Lippincott Williams & Wilkins and Wolters Kluwer: Baltimore, MD, USA, 2013.
[4]
Welsch, M.; Snyder, S.; Stockwell, B. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14(3), 347-361.
[5]
Horton, D.A.; Bourne, G.T.; Smythe, M.L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev., 2003, 103(3), 893-930.
[6]
Brickner, S.J.; Hutchinson, D.K.; Barbachyn, M.R.; Manninen, P.R.; Ulanowicz, D.A.; Garmon, S.A.; Grega, K.C.; Hendges, S.K.; Toops, D.S.; Ford, C.W.; Zurenko, G.E. Synthesis and antibacterial activity of U-100592 and U-100766, Two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem., 1996, 39(3), 673-679.
[7]
Das, B.; Rudra, S.; Yadav, A.; Ray, A.; Raja Rao, A.V.S.; Srinivas, A.S.S.V.; Soni, A.; Saini, S.; Shukla, S.; Pandya, M.; Bhateja, P.; Malhotra, S.; Mathur, T.; Arora, S.K.; Rattan, A.; Mehta, A. Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid. Bioorg. Med. Chem. Lett., 2005, 15(19), 4261-4267.
[8]
Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Kern, W.V.; Pages, J.M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother., 2007, 59(6), 1223-1229.
[9]
Foley, T.L.; Rai, G.; Yasgar, A.; Daniel, T.; Baker, H.L.; Attene-Ramos, M.; Kosa, N.M.; Leister, W.; Burkart, M.D.; Jadhav, A.; Simeonov, A.; Maloney, D.J. 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth. J. Med. Chem., 2014, 57(3), 1063-1078.
[10]
Phoenix, D.A.; Harris, F.; Dennison, S.R. Novel Antimicrobial Agents and Strategies; Wiley-VCH: Weinheim, Germany, 2015.
[11]
Upadhayaya, R.S.; Vandavasi, J.K.; Kardile, R.A.; Lahore, S.V.; Dixit, S.S.; Deokar, H.S.; Shinde, P.D.; Sarman, M.P.; Chattopadhyaya, J. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Eur. J. Med. Chem., 2010, 45(5), 1854-1867.
[12]
Malik, I.; Csollei, J.; Jampilek, J.; Stanzel, L.; Zadrazilova, I.; Hosek, J.; Pospisilova, S.; Cizek, A.; Coffey, A.; O’Mahony, J. The structure–antimicrobial activity relationships of promising class of the compounds containing N-arylpiperazine scaffold. Molecules, 2016, 21(10), 1274.
[13]
Gonec, T.; Malik, I.; Csollei, J.; Jampilek, J.; Stolarikova, J.; Solovic, I.; Mikus, P.; Keltosova, S.; Kollar, P.; O’Mahony, J.; Coffey, A. Synthesis and in vitro antimycobacterial activity of novel N-arylpiperazines containing an ethane-1,2-diyl connecting chain. Molecules, 2017, 22(12), 2100.
[14]
Bak, A.; Kozik, V.; Malik, I.; Jampilek, J.; Smolinski, A. Probability-driven 3D pharmacophore mapping of antimycobacterial potential of hybrid molecules combining phenylcarbamoyloxy and N-arylpiperazine fragments. SAR QSAR Environ. Res., 2018, 29(10), 801-821.
[15]
He, C.; Preiss, L.; Wang, B.; Fu, L.; Wen, H.; Zhang, X.; Cui, H.; Meier, T.; Yin, D. Structural simplification of bedaquiline: The discovery of 3-(4-(N,N-dimethylaminomethyl)phenyl)quinoline-derived antitubercular lead compounds. ChemMedChem, 2017, 12(2), 106-119.
[16]
Lowes, D.; Guiguemde, W.; Connelly, M.; Zhu, F.; Sigal, M.; Clark, J.; Lemoff, A.; Derisi, J.; Wilson, E.; Guy, A.R. Optimization of propafenone analogues as antimalarial leads. J. Med. Chem., 2011, 54(21), 7477-7485.
[17]
Schwinn, F.J. Ergosterol biosynthesis inhibitors. An overview of their history and contribution to medicine and agriculture. Pest Manag. Sci., 1984, 15(1), 40-47.
[18]
Sherald, J.L.; Sisler, H.D. Antifungal mode of action of triforine. Pestic. Biochem. Physiol., 1975, 5(5), 477-488.
[19]
Brent, K.J.; Hollomon, D.W. Fungicide resistance in crop pathogens: how can it be managed?, 2nd ed; Fungicide Resistance Action Committee: Brussels, 2007.
[20]
Wieczorek, D.; Lipok, J.; Borys, K.M.; Adamczyk‐Wozniak, A.; Sporzynski, A. Investigation of fungicidal activity of 3‐piperazine‐bis(benzoxaborole) and its boronic acid analogue. Appl. Organomet. Chem., 2014, 28(5), 347-350.
[21]
Francois, I.E.; Thevissen, K.; Pellens, K.; Meert, E.M.; Heeres, J.; Freyne, E.; Coesemans, E.; Viellevoye, M.; Deroose, F.; Martinez Gonzalez, S.; Pastor, J.; Corens, D.; Meerpoel, L.; Borgers, M.; Ausma, J.; Dispersyn, G.D.; Cammue, B.P. Design and synthesis of a series of piperazine‐1‐carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species. ChemMedChem, 2009, 4(10), 1714-1721.
[22]
Bink, A.; Govaert, G. François, I.E.; Pellens, K.; Meerpoel, L.; Borgers, M.; Van Minnebruggen, G.; Vroome, V.; Cammue, B.P.; Thevissen, K. A fungicidal piperazine-1-carboxamidine induces mitochondrial fission-dependent apoptosis in yeast. FEMS Yeast Res., 2010, 10(7), 812-818.
[23]
Marvanova, P.; Padrtova, T.; Odehnalova, K.; Hosik, O.; Oravec, M.; Mokry, P. Synthesis and determination of physicochemical properties of new 3-(4-arylpiperazin-1-yl)-2-hydroxypropyl 4-alkoxyethoxy-benzoates. Molecules, 2016, 21(12), 1682.
[24]
Marvanova, P.; Padrtova, T.; Pekarek, T.; Brus, J.; Czernek, J.; Mokry, P.; Humpa, O.; Oravec, M.; Jampilek, J. Synthesis and characterization of new 3-(4-arylpiperazin-1-yl)-2-hydroxypropyl 4-propoxybenzoates and their hydrochloride salts. Molecules, 2016, 21(12), 707.
[25]
Vettorazzi, M.; Angelina, E.; Lima, S.; Gonec, T.; Otevrel, J.; Marvanova, P.; Padrtova, T.; Mokry, P.; Bobal, P.; Acosta, L.M.; Palma, A.; Cobo, J.; Bobalova, J.; Csollei, J.; Malik, I.; Alvarez, S.; Spiegel, S.; Jampilek, J.; Enriz, R. An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors. Eur. J. Med. Chem., 2017, 139, 461-481.
[26]
Gu, Z.; Wen, J.; Tang, W.; Wang, W.; Deng, B.; Wu, W.; Qu, T. Glucopyranosyl derivative and application thereof in medicines. Patent CN105461762 A. April 06, 2016.
[27]
Inukai, T.; Sato, H. P'-cyanophenylester der p-(betaalkoxy)
aethoxybenzoesaeure. Patent D2751403 A1. June 01, 1978.
[28]
Tengler, J.; Kapustikova, I.; Stropnicky, O.; Mokry, P.; Oravec, M. Csollei; J.; Jampilek, J. Synthesis of new (arylcarbonyloxy)aminopropanol derivatives and the determination of their physico-chemical properties. Cent. Eur. J. Chem., 2013, 11(11), 1757-1767.
[29]
Zadrazilova, I.; Pospisilova, S.; Masarikova, M.; Imramovsky, A.; Monreal-Ferriz, J.; Vinsova, J.; Cizek, A.; Jampilek, J. Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus. Eur. J. Pharm. Sci., 2015, 77, 197-207.
[30]
Imramovsky, A.; Pesko, M.; Kralova, K.; Vejsova, M.; Stolarikova, J.; Vinsova, J.; Jampilek, J. Investigating spectrum of biological activity of 4- and 5-chloro-2-hydroxy-n-[2-(arylamino)-1-alkyl-2-oxoethyl]benzamides. Molecules, 2011, 16(3), 2414-2430.
[31]
Pauk, K.; Zadrazilova, I.; Imramovsky, A.; Vinsova, J.; Pokorna, M.; Masarikova, M.; Cizek, A.; Jampilek, J. New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species. Bioorg. Med. Chem., 2013, 21(21), 6574-6581.
[32]
Gonec, T.; Zadrazilova, I.; Nevin, E.; Kauerova, T.; Pesko, M.; Kos, J.; Oravec, M.; Kollar, P.; Coffey, A.; O’Mahony, J.; Cizek, A.; Kralova, K.; Jampilek, J. Synthesis and biological evaluation of N-alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides. Molecules, 2015, 20(6), 9767-9787.
[33]
Gonec, T.; Pospisilova, S.; Kauerova, T.; Kos, J.; Dohanosova, J.; Oravec, M.; Kollar, P.; Coffey, A.; Liptaj, T.; Cizek, A.; Jampilek, J. NAlkoxyphenylhydroxynaphthalenecarboxamides and their antimycobacterial activity. Molecules, 2016, 21(8), 1068.
[34]
Imramovsky, A.; Pesko, M.; Monreal-Ferriz, J.; Kralova, K.; Vinsova, J.; Jampilek, J. Photosynthesis-inhibiting efficiency of 4-chloro-2-(chlorophenyl-carbamoyl)phenyl alkyl-carbamates. Bioorg. Med. Chem. Lett., 2011, 21(15), 4564-4567.
[35]
Gonec, T.; Kralova, K.; Pesko, M.; Jampilek, J. Antimycobacterial N-Alkoxyphenylhydroxy-naphthalenecarboxamides affecting photosystem II. Bioorg. Med. Chem. Lett., 2017, 27(9), 1881-1885.
[36]
Tengler, J.; Kapustikova, I.; Pesko, M.; Govender, R.; Keltosova, S.; Mokry, P.; Kollar, P.; O’Mahony, J.; Coffey, A.; Kralova, K.; Jampilek, J. Synthesis and biological evaluation of 2-hydroxy-3-[(2-aryloxyethyl)amino]propyl 4-[(alkoxycarbonyl)-amino]benzoates. Scientific World J., 2013, 2013274570
[37]
Bueno, J. Antitubercular in vitro drug discovery: Tools for begin the search.In: Understanding Tuberculosis-New Approaches to Fighting against Drug Resistance; Cardona, P.J., Ed.; InTech: Rijeka, 2012, pp. 147-168.
[38]
Hamid, R.; Rotshteyn, Y.; Rabadi, L.; Parikh, R.; Bullock, P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. In Vitro, 2004, 18(5), 703-710.
[39]
Martin, A.; Morcillo, N.; Lemus, D.; Montoro, E.; Telles, M.A.; Simboli, N.; Pontino, M.; Porras, T.; Leon, C.; Velasco, M.; Chacon, L.; Barrera, L.; Ritacco, V.; Portaels, F.; Palomino, J.C. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis., 2005, 9(8), 901-906.
[40]
Wang, J.; McIntosh, F.; Radomski, N.; Dewar, K.; Simeone, R.; Enninga, J.; Brosch, R.; Rocha, E.P.; Veyrier, F.J.; Behr, M.A. Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii. Genome Biol. Evol., 2015, 7(3), 856-870.
[41]
Thoen, C.O.; Karlson, A.G.; Ellefson, R.D. Differentiation between Mycobacterium kansasii and Mycobacterium marinum by gas-liquid chromatographic analysis of cellular fatty acids. Appl. Microbiol., 1972, 24(6), 1009-1010.
[42]
Griffith, D.E. Management of disease due to Mycobacterium kansasii. Clin. Chest Med., 2002, 23(3), 613-621.
[43]
Suffness, M.; Douros, J. Current status of the NCI plant and animal product program. J. Nat. Prod., 1982, 45(1), 1-14.
[44]
Kauerova, T.; Kos, J.; Gonec, T.; Jampilek, J.; Kollar, P. Antiproliferative and pro-apoptotic effect of novel nitro-substituted hydroxynaphthanilides on human cancer cell lines. Int. J. Mol. Sci., 2016, 17(8), 1219.
[45]
Zadrazilova, I.; Pospisilova, S.; Pauk, K.; Imramovsky, A.; Vinsova, J.; Cizek, A.; Jampilek, J. In vitro bactericidal activity of 4- and 5-chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]-benzamides against MRSA. BioMed Res. Int., 2015, 2015349534
[46]
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. The 8th Informational
Supplement Document; CLSI: Wayne, PA, USA, 2012, M100-S22.,
[47]
Abate, G.; Mshana, R.N.; Miorner, H. Evaluation of colorimetric assay based on 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 1998, 2(12), 1011-1016.
[48]
Pospisilova, S.; Kos, J.; Michnova, H.; Kapustikova, I.; Strharsky, T.; Oravec, M.; Moricz, A.M.; Bakonyi, J.; Kauerova, T.; Kollar, P.; Cizek, A.; Jampilek, J. Synthesis and spectrum of biological activities of novel N-arylcinnamamides. Int. J. Mol. Sci., 2018, 19(8), 2318.
[49]
Hosek, J.; Bartos, M.; Chudik, S.; Dall’Acqua, S.; Innocenti, G.; Kartal, M.; Kokoska, L.; Kollar, P.; Kutil, Z.; Landa, P.; Marek, R.; Zavalova, V.; Zemlicka, M.; Smejkal, K. Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro. J. Nat. Prod., 2011, 74(4), 614-619.
[50]
Kos, J.; Nevin, E.; Soral, M.; Kushkevych, I.; Gonec, T.; Bobal, P.; Kollar, P.; Coffey, A.; O’Mahony, J.; Liptaj, T.; Kralova, K.; Jampilek, J. Synthesis and antimycobacterial properties of ring-substituted 6-hydroxynaphthalene-2-carboxanilides. Bioorg. Med. Chem., 2015, 23(9), 2035-2043.
[51]
Szabo, E. Isolation and characterization of EBR specific induced chitinases from tobacco (Nicotiana tabacum). Acta Biol. Szeged., 2008, 52(1), 251-252.
41
2
1
